Hitaxa (Desloratadine)

Hitaxa is indicated for several common allergic disorders where histamine release contributes to symptoms.

• Seasonal allergic rhinitis (hay fever) causing sneezing, nasal congestion, and itchy eyes.
• Perennial allergic rhinitis triggered by indoor allergens such as dust mites or pet dander.
• Chronic idiopathic urticaria (hives) presenting with recurrent wheals and itching.
• Relief of symptoms associated with other allergic rhinitis forms, including non‑seasonal or mixed patterns.

• Desloratadine acts as a selective peripheral H1‑receptor antagonist. By binding competitively to H1 receptors on mast cells, basophils and other target cells, it blocks the action of endogenous histamine released during allergic reactions. This inhibition prevents the cascade that leads to vasodilation, increased vascular permeability, and sensory nerve stimulation, thereby reducing the typical signs of allergy without readily crossing the blood‑brain barrier, which limits central sedation.

Like other antihistamines, desloratadine may cause unwanted effects, most of which are mild and transient.

Common

• Headache
• Dry mouth
• Fatigue or mild drowsiness
• Gastrointestinal discomfort such as nausea or abdominal pain

Serious

• Severe skin reactions (e.g., Stevens‑Johnson syndrome, toxic epidermal necrolysis)
• Swelling of the face, lips, tongue, or throat indicating possible angioedema
• Rapid or irregular heartbeat (arrhythmia)
• Signs of liver injury such as jaundice or dark urine

Before starting Hitaxa, certain health considerations should be reviewed to ensure safe use.

• Assess liver function, as desloratadine is metabolized hepatically.
• Use caution in patients with known hypersensitivity to desloratadine or other antihistamines.
• Evaluate renal function in individuals with severe kidney impairment.
• Discuss with a healthcare professional before use during pregnancy or breastfeeding, because safety data are limited.
• Consider potential interaction with other medications that affect the cytochrome P450 system.
• Monitor for signs of cardiac arrhythmia in patients with pre‑existing heart disease.

Desloratadine can interact with other medicines, and some combinations should be avoided or used only under medical supervision.

Avoid

• Strong CYP3A4 inhibitors such as ketoconazole, itraconazole, or clarithromycin, which may increase desloratadine levels.
• Monoamine oxidase inhibitors (MAOIs) taken concurrently, due to potential additive central effects.

Use with caution

• Other antihistamines or sedating drugs, which could enhance drowsiness.
• Alcohol, because it may increase the risk of sedation.
• Medications that prolong the QT interval, such as certain antiarrhythmics or antipsychotics.
• Herbal supplements like St. John’s wort that induce CYP enzymes and could lower drug exposure.